413 related articles for article (PubMed ID: 34043262)
1. The role of interferons type I, II and III in myositis: A review.
Bolko L; Jiang W; Tawara N; Landon-Cardinal O; Anquetil C; Benveniste O; Allenbach Y
Brain Pathol; 2021 May; 31(3):e12955. PubMed ID: 34043262
[TBL] [Abstract][Full Text] [Related]
2. Quantitative whole-body muscle MRI in idiopathic inflammatory myopathies including polymyositis with mitochondrial pathology: indications for a disease spectrum.
Zierer LK; Naegel S; Schneider I; Kendzierski T; Kleeberg K; Koelsch AK; Scholle L; Schaefer C; Naegel A; Zierz S; Otto M; Stoltenburg-Didinger G; Kraya T; Stoevesandt D; Mensch A
J Neurol; 2024 Jun; 271(6):3186-3202. PubMed ID: 38438820
[TBL] [Abstract][Full Text] [Related]
3. Pathophysiological Mechanisms and Treatment of Dermatomyositis and Immune Mediated Necrotizing Myopathies: A Focused Review.
Kamperman RG; van der Kooi AJ; de Visser M; Aronica E; Raaphorst J
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457124
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis.
Pinal-Fernandez I; Quintana A; Milisenda JC; Casal-Dominguez M; Muñoz-Braceras S; Derfoul A; Torres-Ruiz J; Pak K; Dell'Orso S; Naz F; Gutierrez-Cruz G; Milone M; Shelly S; Duque-Jaimez Y; Tobias-Baraja E; Matas-Garcia A; Garrabou G; Padrosa J; Ros J; Trallero-Araguás E; Walitt B; Christopher-Stine L; Lloyd TE; Zhao C; Swift S; Rajan A; Grau-Junyent JM; Selva-O'Callaghan A; Liewluck T; Mammen AL
Ann Rheum Dis; 2023 Jun; 82(6):829-836. PubMed ID: 36801811
[TBL] [Abstract][Full Text] [Related]
5. Identification of distinctive interferon gene signatures in different types of myositis.
Pinal-Fernandez I; Casal-Dominguez M; Derfoul A; Pak K; Plotz P; Miller FW; Milisenda JC; Grau-Junyent JM; Selva-O'Callaghan A; Paik J; Albayda J; Christopher-Stine L; Lloyd TE; Corse AM; Mammen AL
Neurology; 2019 Sep; 93(12):e1193-e1204. PubMed ID: 31434690
[TBL] [Abstract][Full Text] [Related]
6. Identification of Similarities Between Skin Lesions in Patients With Antisynthetase Syndrome and Skin Lesions in Patients With Dermatomyositis by Highly Multiplexed Imaging Mass Cytometry.
Patel J; Ravishankar A; Maddukuri S; Vazquez T; Grinnell M; Werth VP
Arthritis Rheumatol; 2022 May; 74(5):882-891. PubMed ID: 34905301
[TBL] [Abstract][Full Text] [Related]
7. The interferon in idiopathic inflammatory myopathies: Different signatures and new therapeutic perspectives. A literature review.
Gasparotto M; Franco C; Zanatta E; Ghirardello A; Zen M; Iaccarino L; Fabris B; Doria A; Gatto M
Autoimmun Rev; 2023 Jun; 22(6):103334. PubMed ID: 37068699
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pathological features of immune-mediated necrotising myopathies in a single-centre muscle biopsy cohort.
Yang H; Tian X; Zhang L; Li W; Liu Q; Jiang W; Peng Q; Wang G; Lu X
BMC Musculoskelet Disord; 2022 May; 23(1):425. PubMed ID: 35524238
[TBL] [Abstract][Full Text] [Related]
9. Distinct interferon signatures stratify inflammatory and dysimmune myopathies.
Rigolet M; Hou C; Baba Amer Y; Aouizerate J; Periou B; Gherardi RK; Lafuste P; Authier FJ
RMD Open; 2019; 5(1):e000811. PubMed ID: 30886734
[TBL] [Abstract][Full Text] [Related]
10. Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis.
Preuße C; Paesler B; Nelke C; Cengiz D; Müntefering T; Roos A; Amelin D; Allenbach Y; Uruha A; Dittmayer C; Hentschel A; Pawlitzki M; Hoffmann S; Timm S; Louis SL; Dengler NF; Wiendl H; Lünemann JD; Sickmann A; Hervier B; Meuth SG; Schneider U; Schänzer A; Krause S; Tomaras S; Feist E; Hasseli R; Goebel HH; Gallay L; Streichenberger N; Benveniste O; Stenzel W; Ruck T
Acta Neuropathol; 2022 Aug; 144(2):353-372. PubMed ID: 35612662
[TBL] [Abstract][Full Text] [Related]
11. [Idiopathic inflammatory myopathies. A review].
Acosta I; Matamala JM; Jara P; Pino F; Gallardo A; Verdugo R
Rev Med Chil; 2019 Mar; 147(3):342-355. PubMed ID: 31344172
[TBL] [Abstract][Full Text] [Related]
12. Comparison of clinical features between patients with anti-synthetase syndrome and dermatomyositis: Results from the MYONET registry.
Hum RM; Lilleker JB; Lamb JA; Oldroyd AGS; Wang G; Wedderburn LR; Diederichsen LP; Schmidt J; Danieli MG; Oakley P; Griger Z; Phuong TNT; Kodishala C; Vazquez-Del Mercado M; Andersson H; De Paepe B; De Bleecker JL; Maurer B; McCann L; Pipitone N; McHugh N; New RP; Ollier WE; Krogh NS; Vencovsky J; Lundberg IE; ; Chinoy H
Rheumatology (Oxford); 2023 Sep; ():. PubMed ID: 37698987
[TBL] [Abstract][Full Text] [Related]
13. Contribution of Complement, Microangiopathy and Inflammation in Idiopathic Inflammatory Myopathies.
Honda M; Shimizu F; Sato R; Nakamori M
J Neuromuscul Dis; 2024; 11(1):5-16. PubMed ID: 38143369
[TBL] [Abstract][Full Text] [Related]
14. Interferon-signature in idiopathic inflammatory myopathies.
Gallay L; Mouchiroud G; Chazaud B
Curr Opin Rheumatol; 2019 Nov; 31(6):634-642. PubMed ID: 31464706
[TBL] [Abstract][Full Text] [Related]
15. Myostatin in idiopathic inflammatory myopathies: Serum assessment and disease activity.
Mahoudeau A; Anquetil C; Tawara N; Khademian H; Amelin D; Bolko L; Silvestro M; Cin JD; Tendrel B; Tardif V; Mariampillai K; Butler-Browne G; Benveniste O; Allenbach Y
Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12849. PubMed ID: 36168256
[TBL] [Abstract][Full Text] [Related]
16. The type I interferon system in idiopathic inflammatory myopathies.
Lundberg IE; Helmers SB
Autoimmunity; 2010 Apr; 43(3):239-43. PubMed ID: 20187702
[TBL] [Abstract][Full Text] [Related]
17. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity.
Pinal-Fernandez I; Casal-Dominguez M; Carrino JA; Lahouti AH; Basharat P; Albayda J; Paik JJ; Ahlawat S; Danoff SK; Lloyd TE; Mammen AL; Christopher-Stine L
Ann Rheum Dis; 2017 Apr; 76(4):681-687. PubMed ID: 27651398
[TBL] [Abstract][Full Text] [Related]
18. Nailfold videocapillaroscopy alterations in dermatomyositis, antisynthetase syndrome, overlap myositis, and immune-mediated necrotizing myopathy.
Soubrier C; Seguier J; Di Costanzo MP; Ebbo M; Bernit E; Jean E; Veit V; Swiader L; Salort-Campana E; Attarian S; De Paula AM; Kaplanski G; Durand JM; Harlé JR; Schleinitz N
Clin Rheumatol; 2019 Dec; 38(12):3451-3458. PubMed ID: 31440919
[TBL] [Abstract][Full Text] [Related]
19. What is New in Idiopathic Inflammatory Myopathies: Mechanisms and Therapies.
Khadilkar SV; Dhamne MC
Ann Indian Acad Neurol; 2020; 23(4):458-467. PubMed ID: 33223661
[TBL] [Abstract][Full Text] [Related]
20. Idiopathic inflammatory myopathies: from immunopathogenesis to new therapeutic targets.
Haq SA; Tournadre A
Int J Rheum Dis; 2015 Nov; 18(8):818-25. PubMed ID: 26385431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
